Vigilant Biosciences

Vigilant Biosciences is a leading innovator and developer of solutions that assist clinicians in the early detection of oral and oropharyngeal cancer. Vigilant's BeVigilant™ product line includes simple, accurate, and cost-effective point-of-care RAPID tests, enabling healthcare practitioners to improve lives through early intervention. The BeVigilant RAPID test is the first and only technology that measures tumor-initiating and stem cell-associated biomarkers CD44 and total protein, which have been clinically validated in oral rinses to be associated with oral cancer, aiding clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID test uses a simple oral saline rinse collection fluid, which is easy to administer and non-invasive for patients. This test has the potential to benefit adults at risk of oral cancer, especially high-risk populations (i.e., current and former tobacco users, heavy drinkers, and individuals with human papillomavirus HPV-16).